Articles Tagged With:
-
A Link Between Obesity and Asthma Severity
Clinicians should be aware that individualization of treatment for obesity-related asthma may need to include attention to weight reduction to optimize outcomes.
-
Device Could Prevent Recurrent Strokes for Select Patients
FDA approves new non-surgical technology designed to correct condition that can cause repeat events.
-
Is Your Hospital Meeting the National Safety Goals?
Does your hospital have what it takes to comply with the National Patient Safety Goals? -
Drastic Surge in Drug Prices: ‘Unethical and Immoral’
A new business model is emerging in which pharmaceutical companies buy the rights to a drug, then raise the price dramatically. Often, the drugs are produced by one manufacturer, with few or no alternatives.
-
New Report Examines Ethics of Gene Drive Research
A recent report from the National Academies of Sciences, Engineering, and Medicine examines the ethics of gene drive research.
-
Physicians Paid to Refer Patients: ‘Fundamental and Clear’ Ethical Violation
The nonprofit hospital system Broward Health in Florida recently agreed to pay $70 million to settle allegations that it engaged in “improper financial relationships” under laws prohibiting kickbacks for patient referrals.
-
Provide High-Quality Ethics Education on a Limited Budget
Medical institutions didn’t always understand the importance of ethics to physician training, notes Timothy Lahey, MD, MMSc, chair of the clinical ethics committee at Lebanon, NH-based Dartmouth-Hitchcock Medical Center, and associate professor at Dartmouth’s Geisel School of Medicine.
-
New Palliative Care Policy Aims to Reduce Barriers
A new palliative care policy statement from a leading heart and stroke organization aims to reduce barriers that prevent many patients from receiving palliative care. -
Conflicts on Prognosis Occur Over Half the Time Between Physicians and Surrogate Decision-Makers
Conflicts between physicians and surrogate decision-makers involving the patient’s prognosis occur more than half the time, according to a recent study.
-
Pharmacologic Management of Type 2 Diabetes Mellitus: Part 2
This two-part series of articles will address pharmacological agents, except insulin, used to manage type 2 diabetes mellitus. Part 1 covered sodium glucose co-transporter-2 inhibitors, incretin-based therapies, amylin analog, and dopamine receptor agonists. Part 2 will focus on biguanides, thiazolidinediones, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, and bile acid resins, as well as the authors’ treatment recommendations. Appendix A (http://bit.ly/2eyB4Px) is a comprehensive table of the effectiveness and costs of various combination therapies.